Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 2:13:1015614.
doi: 10.3389/fendo.2022.1015614. eCollection 2022.

Obesity and related comorbidities in a large population-based cohort of subjects with type 1 diabetes in Catalonia

Idoia Genua  1   2   3 , Josep Franch-Nadal  4   5   6 , Elena Navas  7 , Manel Mata-Cases  4   6   8 , Gabriel Giménez-Pérez  9   10 , Bogdan Vlacho  3   4   6 , Didac Mauricio  1   4   6   11 , Albert Goday  2   12   13
Affiliations
Review

Obesity and related comorbidities in a large population-based cohort of subjects with type 1 diabetes in Catalonia

Idoia Genua et al. Front Endocrinol (Lausanne). .

Abstract

Introduction: Obesity, an increasing global health problem, can affect people with other disease conditions. The prevalence of obesity in people with type 1 diabetes (T1D) is not well known. The aim of this study was to describe extensively the characteristics and prevalence of different classes of obesity according to BMI (body mass index) categories in a large cohort of patients with T1D.

Material and methods: This was a retrospective, cross-sectional study in Catalonia. We reviewed all patients with T1D diagnosis, ≥ 18 years old and with BMI data from the SIDIAP database. Sociodemographic and clinical data, cardiovascular risk factors, laboratory parameters and concomitant medications were collected.

Results: A total of 6,068 patients with T1D were analyzed. The prevalence of obesity in the total sample was 18% (13.8% with class 1 obesity [BMI 30-34.9 kg/m2]). Patients with obesity had a higher prevalence of other cardiovascular risk factors (i.e. hypertension was 61.4% vs. 37.5%; dyslipidemia 63.6% vs 44%, and chronic kidney disease 38.4% vs. 24.4%; p<0.001 in all cases) and poorer control of them. The higher prevalence was regardless of sex, age and duration of diabetes. The increase in these comorbidities was noticeable from a BMI > 25 kg/m2. Patients with obesity did not have poorer glycemic control.

Conclusion: The presence of obesity in people with T1D is frequent and cardiovascular risk factors are more common and more poorly controlled in T1D patients with obesity.

Keywords: Obesity; cardiovascular risk factors; comorbidities; metabolic syndrome; type 1 diabetes.

PubMed Disclaimer

Conflict of interest statement

IG received support for attending meetings form Boehringer Ingelheim, Lilly, MSD, Novo-Nordisk and Sanofi. JF-N received advisory and/or speaking fees from Astra-Zeneca, Ascensia, Boehringer Ingelheim, GSK, Lilly, MSD, Novartis, Novo Nordisk and Sanofi. Received research grants to the institution from Astra-Zeneca. GSK, Lilly, MSD, Novartis, Novo Nordisk, Sanofi and Boehringer. DM has received advisory and/or speaking fees from Almirall, Esteve, Ferrer, Janssen, Lilly, Menarini, MSD, NovoNordisk and Sanofi. GG-P has received speaking fees from Lilly and Astra-Zeneca. MM-C has received advisory honorarium from for Astra-Zeneca, Bayer, Boehringer Ingelheim, GSK, Lilly, MSD, NOVARTIS, NovoNordisk, Sanofi; speaker honorarium from Astra- Zeneca, Bayer, Boehringer Ingelheim, GSK, Lilly, Menarini, MSD, Novartis, NovoNordisk, and Sanofi; and research grants to institution from Astra-Zeneca, GSK, Lilly, MSD, Novartis, NovoNordisk, and Sanofi. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. van der Schueren B, Ellis D, Faradji RN, Al-Ozairi E, Rosen J, Mathieu C. Obesity in people living with type 1 diabetes. Lancet Diabetes Endocrinol (2021) 9:776–85. doi: 10.1016/S2213-8587(21)00246-1 - DOI - PubMed
    1. Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, Dimeglio LA, et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018. Diabetes Technol Ther (2019) 21:66–72. doi: 10.1089/dia.2018.0384 - DOI - PMC - PubMed
    1. van Mark G, Lanzinger S, Barion R, Degenhardt M, Badis S, Noll H, et al. Patient and disease characteristics of adult patients with type 1 diabetes in Germany: An analysis of the DPV and DIVE databases. Ther Adv Endocrinol Metab (2019) 10 :1–12. doi: 10.1177/2042018819830867 - DOI - PMC - PubMed
    1. Lavens A, Nobels F, de Block C, Oriot P, Verhaegen A, Chao S, et al. Effect of an integrated, multidisciplinary nationwide approach to type 1 diabetes care on metabolic outcomes: An observational real-world study. Diabetes Technol Ther (2021) 23(8):565–76. doi: 10.1089/dia.2021.0003 - DOI - PubMed
    1. Vestberg D, Rosengren A, Olsson M, Gudbjörnsdottir S, Svensson AM, Lind M. Relationship between overweight and obesity with hospitalization for heart failure in 20,985 patients with type 1 diabetes: A population-based study from the Swedish national diabetes registry. Diabetes Care (2013) 36(9):2857–61. doi: 10.2337/dc12-2007 - DOI - PMC - PubMed

Publication types